Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Patients with Neuromyelitis Optica
jRCTs031180152Completed
- Sponsor
- National Center of Neurology and Psychiatry
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of tocilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by National Center of Neurology and Psychiatry. Primary endpoints: Adverse events after initiation of tocilizumab and Annual relapse rate after tocilizumab vs pretreatment. Started Jun 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCTs031180152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180152.